Concord Drugs Ltd Approves FY2026 Quarter Results; Profitability Improves Despite Equity Dilution
Concord Drugs Limited has reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved the statements, which were also reviewed by the company's statutory auditors.The company’s profitability performance was highlighted as improving during the quarter, offsetting the impact of increased equity shares resulting from a recent preferential issue. This strengthening in earnings generation occurred despite the dilution arising from the allotment of 31,75,000 equity shares at ₹36.50 per share.
The financial data for Concord Drugs Ltd, presented in Rs. Lakhs, is summarized below:
Standalone Financial Results (Unaudited)
| Particulars | Quarter Ended 30-Jun-26 | Quarterly Ended 31-Mar-26 | 30-Jun-25 (Un Audited) | Year Ended 31-Mar-26 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 3,788.80 | 7,873.68 | ||
| Other Operating Income | 2,093.88 | 1.08 | 1,360.64 | 3.44 |
| Total Revenue | 2,094.70 | 3,789.89 | 1,360.64 | 7,877.13 |
| Total Expenses | 48.73 | 53.24 | 1,344.81 | 7,729.81 |
| Profit Before Tax | 154.49 | 74.76 | 15.83 | 147.32 |
| Profit for the Period | 111.40 | 52.80 | 177 | 105.50 |
| Paid up Capital | 1,317.50 | 1,317.50 | 1,000.00 | 1,317.50 |
Consolidated Financial Results (Unaudited)
The consolidated results reflected the performance of the company and its subsidiaries for the corresponding periods. Key figures are as follows:| Particulars | Quarter Ended 30-Jun-26 | Quarterly Ended 31-Mar-26 | 30-Jun-25 (Un Audited) | Year Ended 31-Mar-26 |
|---|---|---|---|---|
| Revenue from Operations | 3,788.80 | 7,873.68 | ||
| Other Operating Income | 2,093.88 | 1.08 | 1,360.64 | 3.44 |
| Total Revenue | 2,094.70 | 3,789.89 | 1,360.64 | 7,877.13 |
| Total Expenses | 1,652.38 | 3,507.05 | 1,081.22 | 6,802.96 |
| Profit Before Tax | 154.49 | 74.76 | 15.83 | 147.32 |
| Profit for the Period | 111.40 | 52.80 | 177 | 105.50 |
| Paid up Capital | 1,317.50 | 1,317.50 | 1,000.00 | 1,317.50 |
Investor Observations and Auditing Review
The results were prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. The company noted that although the equity share capital increased by over 33%, the improvement in Earnings Per Share (EPS) during the quarter demonstrated stronger earnings generation despite the dilution from the preferential allotment.The independent auditors conducted a review of both the standalone and consolidated unaudited quarterly financial results. Their review confirmed that the statements were prepared in accordance with Ind AS 34, Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, and correctly disclosed the necessary information. The consolidated statement also included the results of one subsidiary, which reported total revenues of Rs 36.54 lakhs and a net profit after tax of Rs.0.23 lakhs for the quarter ended June 30, 2026.
Stock Price Movement
Concord Drugs Ltd settled at ₹73.82 after closing today, ticking up 3.67%. The shares experienced a volatile session, moving between an intraday low of ₹71.60 and a high of ₹74.70.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.